Summary: Brief exposure to Rapamycin, a promising anti-aging drug with positive effects on health and lifespan, has the same effect as long-term exposure to the drug in animal models. The results pave the way for testing the effects of short-term exposure to rapamycin on human lifespan.
source: Max Planck Institute
Imagine you can take a drug that prevents the deterioration of ageing and keeps you healthy. Scientists are trying to find a drug that has these effects.
Rapamycin is currently the most promising anti-aging drug, known for its positive effects on life and longevity in experimental studies on laboratory animals.
To obtain the maximum beneficial effects of the drug, it is often given for life. However, even with the lower doses used to prevent age-related deterioration, negative side effects may occur, and it is always advisable to use the lowest effective dose.
A research group at the Max Planck Institute for Biology of Aging in Cologne, Germany has shown in laboratory animals that short exposure to rapamycin has the same positive effects as lifelong treatment opening new doors for potential application in humans.
Combating the negative effects of aging is increasingly becoming the focus of research scientists. Lifestyle changes can improve the health of older adults, but they alone are not enough to prevent diseases of aging. The reuse of existing drugs for “aging protection” provides an additional weapon in preventing the deterioration associated with ageing.
One of the most promising anti-aging drugs, rapamycin is a cell growth inhibitor and immunosuppressant commonly used in cancer treatment and after organ transplantation.
“At clinically used doses, rapamycin can have unwanted side effects, but to use the drug in the prevention of age-related deterioration, these effects must be absent or minimal. Therefore, we wanted to know when and for how long we need to give rapamycin in order to achieve Same effects as treatment for life,” explains Dr. Paula Juricic, principal investigator of the study in the department of Professor Linda Partridge, Director at the Max Planck Institute for Biology of Aging.
Show only for a short time
Scientists tested different time windows for short-term drug administration in fruit flies and found that a short period of two weeks of rapamycin treatment in young and adult flies protects them from age-related diseases in the gut and extends their lives.
The corresponding short time window, 3 months of treatment starting at 3 months of age in young and adult mice, had similar beneficial effects on gut health when they were middle-aged.
“These short drug treatments in early adulthood produced just as strong protection as the continuous treatment started at the same time.
We also found that rapamycin treatment had the strongest and best effects when administered early in life than in middle age. On the other hand, when flies were treated with rapamycin late in their lives, it had no effect at all.
“Therefore, rapamycin memory is primarily activated in early adulthood,” explains Dr. Thomas Lesch, co-author of the paper.
One step closer to apps
“We have found a way to circumvent the need for long-term chronic rapamycin, so its application to humans may be more practical,” says Dr Yu-Xuan Lu, who is also a co-author on the research. Professor Linda Partridge, lead author of the study, comments:
“It will be important to discover if the anti-aging effects of rapamycin can be achieved in mice and humans with the start of treatment later in life, as the treatment period should ideally be reduced. Intermittent doses may also be possible.
“This study opened new doors, but it also raised many new questions.”
About this research on aging and pharmacology news
author: Maren Berghof
source: Max Planck Institute
Contact: Marien Berghof – Max Planck Institute
picture: The image is credited to the Max Planck Institute
original search: open access.
“Long-term bacterial protection from short rapamycin therapy in early adulthood by persistently increasing intestinal autophagy.Written by Linda Partridge et al. aging nature
Long-term bacterial protection from short rapamycin therapy in early adulthood by persistently increasing intestinal autophagy.
The licensed drug rapamycin has the potential to be repurposed for gyroprotein protection. The main challenge is to avoid harmful side effects from continuous doses.
Here we show that the aging-protective effects of chronic rapamycin treatment can be obtained with a short drug pulse in early adulthood in females. fruit fly and mice.
in fruit flyEarly and brief rapamycin treatment in adults extends life span and attenuates age-related deterioration in the gut to the same degree as lifetime doses. Persistent memory of early treatment was mediated by elevated autophagy in intestinal enterocytes, accompanied by increased levels of intestinal LManV and lysozyme.
A brief rise in autophagy in early adulthood led to an increase in autophagy in the long term. In mice, early 3-month treatment also induced an effect on memory, with similar maintenance to chronic treatment, of lysozyme distribution, Man2B1 level in intestinal crypts, Paneth cell architecture and gut barrier function, even 6 months after rapamycin withdrawal.